{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:58:35Z","timestamp":1789397915647,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Oxaliplatin (OXA), a third-generation platinum derivative, has become one of the main chemotherapeutic drugs for colorectal cancer and other cancers, but reports of adverse reactions are also increasing with the extensive application of OXA. In this study, post-marketing surveillance was carried out to investigate the safety profile of OXA in a real-world setting in Chinese cancer patients to provide a reference for the rational application of OXA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with cancer who received OXA-based chemotherapy in 10 tertiary hospitals in Hubei Province, China, between May 2016 and November 2016 were enrolled. A central registration method was used to document patients\u2019 demographics, clinical use, and any incidence of adverse reactions to OXA. All adverse drug reactions (ADRs) were collected and analyzed to assess causality, severity, treatment, and outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 3687 patients were enrolled in this study. Approximately 64.6% of the patients were male, and 68.8% were aged 50-70 years, with a mean age of 55.3 years. The proportions of patients diagnosed with colorectal and gastric cancers were 59.3% and 31.6%, respectively. In this study, the overall incidence of ADRs and serious ADRs was 42.7% and 1.3%, respectively. The most common ADRs were gastrointestinal disorders (25.7%), blood disorders (21.1%), and peripheral nervous system disorders (8.0%). The serious ADRs identified were hypersensitivity reactions, thrombocytopenia, abnormal hepatic function, and leukopenia\/neutropenia. The median onset of gastrointestinal toxicity, myelosuppression, peripheral neurotoxicity, and abnormal hepatic function was 1\u00a0d, 5\u00a0d, 1\u00a0d, and 14\u00a0d, respectively. The majority (84.7%) of hypersensitivity reactions were mild to moderate, and the median time to onset of these reactions was within the first 20\u00a0min of OXA infusion. Almost 88.0% of patients who experienced ADRs recovered or improved with treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data suggest that OXA-induced ADRs are very common in Chinese patients with cancer; however, more attention should be paid to hypersensitivity reactions caused by OXA. This study provides a valuable reference regarding the safe application of OXA in a real-world setting.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.757196","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T07:08:25Z","timestamp":1634800105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Zaoqin","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianguo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.10.2159","article-title":"A Review of Oxaliplatin and its Clinical Use in Colorectal Cancer","volume":"5","author":"Grothey","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9189","article-title":"Comparative Effectiveness and Safety Between Oxaliplatin-Based and Cisplatin-Based Therapy in Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.5007","article-title":"NCCN Guidelines Updates: Pancreatic Cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2014.04.039","article-title":"Oxaliplatin Salvage for Recurrent Ovarian Cancer: A Single Institution's Experience in Patient Populations With Platinum Resistant Disease or a History of Platinum Hypersensitivity[J]","volume":"134","author":"Taylor","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, Fluorouracil and Leukovorin as Adjuvant Treatment for Colon Cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.02.006","article-title":"A Systematic Review of Salvage Therapy to Patients With Metastatic Colorectal Cancer Previously Treated With Fuorouracil, Oxaliplatin and Irinotecan +\/- Targeted Therapy","volume":"40","author":"Nielsen","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000042","article-title":"The Efficacy and Safety of Hepatic Arterial Infusion of Oxaliplatin Plus Intravenous Irinotecan, Leucovorin and Fuorouracil in Colorectal Cancer With Inoperable Hepatic Metastasis","volume":"28","author":"Volovat","year":"2016","journal-title":"J Chemother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3294-9","article-title":"Comparison Between Hypersensitivity Reactions to Cycles of Modified FOLFOX6 and XELOX Therapies in Patients With Colorectal Cancer","volume":"79","author":"Ohta","year":"2017","journal-title":"Cancer Chemoth Pharm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37777","article-title":"Gastrointestinal Toxic Effects in Patients With Cancer Receiving Platinum-Based Therapy","volume":"11","author":"Abu-Sbeih","year":"2020","journal-title":"J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.154056","article-title":"Oxaliplatin-Induced Acute Thrombocytopenia","volume":"12","author":"Erdem","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09942-w","article-title":"Oxaliplatin\u2212induced Peripheral Neuropathy: Clinical Features, Mechanisms, Prevention and Treatment","volume":"268","author":"Kang","year":"2021","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1179\/1973947814Y.0000000204","article-title":"Oxaliplatin-Induced Hypersensitivity Reaction: Underlying Mechanisms and Management","volume":"27","author":"Aroldi","year":"2015","journal-title":"J\u00a0Chemother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved Overall Survival With Oxaliplatin, Fuorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial","volume":"27","author":"Andre","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clcc.2011.10.004","article-title":"Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity","volume":"11","author":"Hoff","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.6004\/jnccn.2019.5014","article-title":"NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer","volume":"17","author":"Messersmith","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/sonc.2002.35524","article-title":"Oxaliplatin-Related Side Effects:Characteristics and Management","volume":"29","author":"Cassidy","year":"2002","journal-title":"Semin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1039\/c8dt00838h","article-title":"The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN Guidelines Insights: Antiemesis, Version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/07357900701470739","article-title":"A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience","volume":"25","author":"Xu","year":"2007","journal-title":"Cancer Investig"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3119-2","article-title":"Myelosuppression by Chemotherapy in Obese Patients With Gynecological Cancers","volume":"78","author":"Kamimura","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds074","article-title":"Oxaliplatin-Related Thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.11.005","article-title":"Acute Oxaliplatin-Induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review","author":"Phull","year":"2016","journal-title":"Clin Colorectal Canc"},{"key":"B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000178163","article-title":"Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience","volume":"76","author":"Polyzos","year":"2009","journal-title":"Oncology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity Reaction and Acute Immunemediated Thrombocytopenia From Oxaliplatin:Two Case Reports and a Review of the Literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","article-title":"The Incidence of Acute Oxaliplatin-Induced Neuropathy and its Impact on Treatment in the First Cycle: A Systematic Review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03511.x","article-title":"Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia are Frequent Oxaliplatin-Associated Liver Lesions and Partially Prevented by Bevacizumab in Patients With Hepatic Colorectal Metastasis","volume":"56","author":"Rubbia-Brandt","year":"2010","journal-title":"Histopathology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v5.i3.30","article-title":"Hepatic Histopathology and Postoperative Outcome After Preoperative Chemotherapy for Chinese Patients With Colorectal Liver Metastases","volume":"5","author":"Lu","year":"2013","journal-title":"World J Gastrointest Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1540","article-title":"Oxaliplatin-Induced Hepatic Sinusoidal Obstruction Syndrome in a Patient With Gastric Cancer: A Case Report","volume":"8","author":"Liu","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.suronc.2016.05.030","article-title":"The Influence of Chemotherapy-Associated Sinusoidal Dilatation on Short-Term Outcome After Partial Hepatectomy for Colorectal Liver Metastases: A Systematic Review With Meta-Analysis","volume":"25","author":"van Mierlo","year":"2016","journal-title":"Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/bjs.10572","article-title":"Systematic Review of the Influence of Chemotherapy-Associated Liver Injury on Outcome After Partial Hepatectomy for Colorectal Liver Metastases","volume":"104","author":"Zhao","year":"2017","journal-title":"Br J Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13632","article-title":"Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting From Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis","volume":"39","author":"Hisaka","year":"2019","journal-title":"Anticancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2016.17.4.1637","article-title":"Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches","volume":"17","author":"Bano","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity Reactions Related to Oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10147-009-0883-6","article-title":"Oxaliplatin-Induced Allergic Reaction in Patients With Colorectal Cancer in Japan","volume":"14","author":"Shibata","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-1","article-title":"Hypersensitivity to Oxaliplatin: Clinical Features and Risk Factors","volume":"15","author":"Parel","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.03.012","article-title":"Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol","volume":"37","author":"Okayama","year":"2015","journal-title":"Clin Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12156","article-title":"A Retrospective Analysis of the Risk Factors for Allergic Reactions Induced by the Administration of Oxaliplatin","volume":"24","author":"Yamauchi","year":"2015","journal-title":"Eur J Cancer Care"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(10)60064-2","article-title":"Characteristics and Risk Factors of Oxaliplatin-Related Hypersensitivity Reactions","volume":"109","author":"Shao","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000205263","article-title":"Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review","volume":"76","author":"Kim","year":"2009","journal-title":"Oncology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-021-2387-1","article-title":"Clinical Features of Oxaliplatin-Related Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis","volume":"41","author":"Li","year":"2021","journal-title":"Curr Med Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i38.5427","article-title":"Oxaliplatin-Induced Severe Anaphylactic Reactions in Metastatic Colorectal Cancer:Case Series Analysis","volume":"18","author":"Wang","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj042","article-title":"Hypersensitivity Reactions to Oxaliplatin: Experience in a Single Institute","volume":"17","author":"Siu","year":"2006","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.06.007","article-title":"Desensitization to Oxaliplatin With Two Stages of Premedication in a Patient With Metastatic Rectal Cancer","volume":"30","author":"Nozawa","year":"2008","journal-title":"Clin Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T07:08:28Z","timestamp":1634800108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":47,"alternative-id":["10.3389\/fonc.2021.757196"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.757196","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"article-number":"757196"}}